Edesa Biotech launches public offering of common shares

Edesa Biotech, Inc. (Nasdaq: EDSA) announced the commencement of an underwritten public offering of common shares, or pre-funded warrants in lieu thereof, along with accompanying common share warrants, according to a company statement.

The Toronto-based clinical-stage biopharmaceutical company said it expects to grant underwriters a 30-day option to purchase additional common shares and warrants totaling up to 15% of the shares offered under the same terms and conditions.

Guggenheim Securities is serving as the sole book-running manager for the offering.

Edesa said it intends to use net proceeds for general corporate purposes, which may include working capital, capital expenditures, and research and development and manufacturing expenses.

The offering is being made under a shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission on Sept. 9, 2025. The company noted the offering remains subject to market and other conditions, with no assurance as to whether or when it may be completed, or the final size or terms.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• RenovoRx regains Nasdaq minimum bid price compliance
• Sky Century Investment responds to OTC Markets stock promotion inquiry